

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sally Mellor, et al.

Examiner: Elizabeth Kemmerer

Serial No.: 10/538,431

Art Unit: 1646

Filed: January 9, 2006

Docket: 18940

For: METHOD OF DIAGNOSIS,
TREATMENT AND USEFUL AGENTS
FOR CONDITIONS CHARACTERISED
BY MODULATION IN THE LEVEL
OF ACTIVIN β C

Dated: February 12, 2008

Confirmation No.: 3184

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. PCT International Publication No. WO 98/22492, published May 28, 1998;
2. Mellor S.L. et al., "Localization of Activin β_A -, β_B -, and β_C -Subunits in Human Prostate and Evidence for Formation of New Activin Heterodimers of β_C -Subunit", *The Journal of Clinical Endocrinology & Metabolism* 85(12):4851-4858 (2000);
3. European Patent Publication No. 1 174 149 A1, published January 23, 2002;

CERTIFICATE OF ELECTRONIC FILING

I hereby certify that this correspondence is being deposited with the United States Patent & Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website.

Dated: February 12, 2008


Xiaochun Zhu

4. Gold E.J. et al., "Changes in Activin and Activin Receptor Subunit Expression in Rat Liver During the Development of CC14-Induced Cirrhosis", *Molecular and Cellular Endocrinology* 201:143-153 (2003);
5. Mellor S.L. et al., "Activin β_C -Subunit Heterodimers Provide a New Mechanism of Regulating Activin Levels in the Prostate", *Endocrinology* 144(10):4410-4419 (2003);
6. Vejda S. et al., "Expression and Dimerization of the Rat Activin Subunits β_C and β_E : Evidence for the Formation of Novel Activin Dimers", *Journal of Molecular Endocrinology* 28:137-148 (2002);
7. Thomas T.Z. et al., "Inhibins, Activins, and Follistatins: Expression of mRNAs and Cellular Localization in Tissues from Men with Benign Prostatic Hyperplasia", *The Prostate* 34:34-43 (1998);
8. Risbridger G.P. et al., "The Contribution of Inhibins and Activins to Malignant Prostate Disease", *Molecular and Cellular Endocrinology* 180:149-153 (2001);
9. Dowling C.R. et al., "The Role of Inhibins and Activins in Prostate Cancer Pathogenesis", *Endocrine-Related Cancer* 7:243-256 (2000);
10. Wakui M. et al., "Genes Highly Expressed in the Early Phase of Murine Graft-Versus-Host Reaction", *Biochemical and Biophysical Research Communications* 282(1):200-206 (2001);
11. GenexBioscience, Sept 2002 'Anti-Activin Beta-C: Polyclonal Antibody Produced in Rabbits Immunized with a Synthetic KLH-Conjugated Peptide', retrieved 5 February 2004, URL: <http://www.genexbioscience.com/products.cfm?productID=146>. Also, waybackmachine: http://web.archive.org/web/*/www.genexbioscience.com, retrieved on 5 February 2002;
12. Vejda S. et al., "Expression of Activins C and E Induces Apoptosis in Human and Rat Hepatoma Cells", *Carcinogenesis* 24(11):1801-1809 (2003);
13. PCT International Publication No. WO 98/02751, published January 22, 1998;
14. Su G.H. et al., "ACVR1B (ALK-4, Activin Receptor Type 1B) Gene Mutations in Pancreatic Carcinoma", *PNAS* 98(6):3254-3257 (2001);
15. Bunin B.A. et al., "The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1,4-Benzodiazepine Library", *Proc. Natl. Acad. Sci. USA* 91:4708-4712 (1994);

16. Burke B. et al., "Microinjection of mRNA Coding for an Anti-Golgi Antibody Inhibits Intracellular Transport of a Viral Membrane Protein", *Cell* 36:847-856 (1984);
17. Chang H. et al., "Studying TGF- β Superfamily Signaling by Knockouts and Knockins", *Molecular and Cellular Endocrinology* 180:39-46 (2001);
18. Chen X. et al., "A Transcriptional Partner for MAD Proteins in TGF- β Signalling", *Nature* 383:691-696 (1996);
19. Chen X. et al., "Smad4 and FAST-1 in the Assembly of Activin-Responsive Factor", *Nature* 389:85-89 (1997);
20. Cole S.P.C. et al., "The EBV-Hybridoma Technique and its Application to Human Lung Cancer", *Monoclonal Antibodies and Cancer Therapy*, pp. 77-96 (1985);
21. de Kretser D.M. et al., "Activin A and Follistatin: Their Role in the Acute Phase Reaction and Inflammation", *Journal of Endocrinology* 161:195-198 (1999);
22. DeWitt S.H. et al., "Diversomers": An Approach to Nonpeptide, Nonoligomeric Chemical Diversity", *Proc. Natl. Acad. Sci. USA* 90:6909-6913 (1993);
23. Esquela A.F. et al., "Transient Down-Regulation of Inhibin- β C Expression Following Partial Hepatectomy", *Biochemical and Biophysical Research Communications* 235:553-556 (1997);
24. Evans L.W. et al., "Development, Validation and Application of an Ultra-Sensitive Two-Site Enzyme Immunoassay for Human Follistatin", *Journal of Endocrinology* 156:275-282 (1998);
25. Fang J. et al., "Genes Coding for Mouse Activin β C and β E are Closely Linked and Exhibit a Liver-Specific Expression Pattern in Adult Tissues", *Biochemical and Biophysical Research Communications* 231:655-661 (1997);
26. Groome N.P. et al., "Enzyme Immunoassays for Inhibins, Activins and Follistatins", *Molecular and Cellular Endocrinology* 180:73-77 (2001);
27. Hötten G. et al., "Cloning of a New Member of the TGF- β Family: A Putative New Activin β C Chain", *Biochemical and Biophysical Research Communications* 206(2):608-613 (1995);

28. Hübner G. et al., "Activin: A Novel Player in Tissue Repair Processes", *Histol Histopathol* 14:295-304 (1999);
29. Kozbor D. et al., "The Production of Monoclonal Antibodies from Human Lymphocytes", *Immunology Today* 4(3):72-79 (1983);
30. Kron R. et al., "Expression of Human Activin C Protein in Insect Larvae Infected with a Recombinant Baculovirus", *Journal of Virological Methods* 72:9-14 (1998);
31. Lau A.L. et al., "Activin β C and β E Genes are Not Essential for Mouse Liver Growth, Differentiation, and Regeneration", *Molecular and Cellular Biology* 20(16):6127-6137 (2000);
32. Lau A.L. et al., "Structural Analysis of the Mouse Activin β C Gene", *Biochimica et Biophysica Acta* 1307:145-148 (1996);
33. Lebrun J-J et al., "Roles of Pathway-Specific and Inhibitory Smads in Activin Receptor Signaling", *Molecular Endocrinology* 13:15-23 (1999);
34. Luisi S. et al., "Expression and Secretion of Activin A: Possible Physiological and Clinical Implications", *European Journal of Endocrinology* 145:225-236 (2001);
35. McDowell N. et al., "Activin as a Morphogen in *Xenopus* Mesoderm Induction", *Cell & Developmental Biology* 10:311-317 (1999);
36. McFarlane J.R. et al., "Measurement of Activin in Biological Fluids by Radioimmunoassay, Utilizing Dissociating Agents to Remove the Interference of Follistatin", *European Journal of Endocrinology* 134:481-489 (1996);
37. Morgan D.O. et al., "Analysis of Intracellular Protein Function by Antibody Injection", *Immunology Today* 9(3):84-88 (1988);
38. Moore A. et al., "Measuring Transferrin Receptor Gene Expression by NMR Imaging", *Biochimica et Biophysica Acta* 1402:239-249 (1998);
39. O'Bryan M.K. et al., "Cloning and Regulation of the Rat Activin β E Subunit", *Journal of Molecular Endocrinology* 24:409-418 (2000);
40. Oda S. et al., "Molecular Cloning and Functional Analysis of a New Activin β Subunit: A Dorsal Mesoderm-Inducing Activity in *Xenopus*", *Biochemical and Biophysical Research Communications* 210(2):581-588 (1995);


41. Pangas S.A. et al., "Activin Signal Transduction Pathways", *TEM* 11(8):309-314 (2000);
42. Schmitt J. et al., "Structure, Chromosomal Localization, and Expression Analysis of the Mouse Inhibin/Activin β_C (*Inhbc*) Gene", *Genomics* 32:358-366 (1996);
43. Stein C.A. et al., "Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review", *Cancer Research* 48:2659-2668 (1988);
44. van der Krol A. et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences", *BioTechniques* 6(10):958-976 (1988);
45. Wedemeyer N. et al., "Flow Cytometric Quantification of Competitive Reverse Transcription-PCR Products", *Clinical Chemistry* 48(9):1398-1405 (2002);
46. Weissleder R. et al., "In Vivo Magnetic Resonance Imaging of Transgene Expression", *Nature Medicine* 6(3):351-354 (2000);
47. Wrana J.L. et al., "The Smad Pathway", *Cytokine & Growth Factor Reviews* 11:5-13 (2000); and
48. Zhang Y-Q et al., "Reciprocal Expression of mRNA for Inhibin β_C and β_A Subunits in Hepatocytes", *Endocrine Journal* 44(5):759-764 (1997).

References 1-11 were cited in an International Search Report dated February 24, 2004 received from the Australian Patent Office. A copy of the International Search Report was previously submitted by Applicants on June 10, 2005. References 2, 12 and 13 were cited in a Supplementary Partial Search Report dated June 28, 2006 received from the European Patent Office. Reference 14 was cited in an Examination Report issued in respect of corresponding Indian Patent Application No. 3090/DELNP/2005 dated April 9, 2007. References 15-48 are discussed in the specification, including the Background section of the specification.

Applicants are submitting copies of the references, as required by 37 C.F.R. §1.98 (a)(2)(i) and (ii), together with copies of the Supplementary Partial European Search Report and the Examination Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Xiaochun Zhu', written in a cursive style.

Xiaochun Zhu
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343
XZ:ab/dg